Meeting
2011 ASCO Annual Meeting
Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study.
Authors
B. Chibaudel
Hôpital Saint-Antoine, Paris, France
B. Chibaudel , C. Tournigand , M. Mabro , M. Bennamoun , P. Artru , S. Nguyen , J. Bachet , N. Aissat , H. Blons , P. Laurent-Puig , A. De Gramont , T. Andre
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00655499
Citation
J Clin Oncol 29: 2011 (suppl; abstr 3573)
Abstract #
3573
Poster Bd #
14E
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Results of the Quad wild type arm of the AGITG ICECREAM study: A randomised phase II study of cetuximab alone or in combination with irinotecan in patients with refractory metastatic colorectal cancer with no mutations in KRAS, NRAS, BRAF or PIK3CA.
First Author: Jeremy David Shapiro
![PULSE: An open-label, phase II study assessing double positivity (phospho-insulin-growth factor receptor-1 [pIGF-IR] and matrilysin [MMP7]) expression, as a predictive marker of resistance in previously untreated metastatic colorectal cancer (mCRC) wild-type KRAS patients (pts) treated with panitumumab plus mFOLFOX6—A GEMCAD study. .](https://d201v5jt9ylckg.cloudfront.net/102/6682/61160/61160_poster_pv.jpg)
First Author: J. Maurel
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase 1b/2, open-label study of amivantamab monotherapy or in combination with standard-of-care chemotherapy in participants with advanced or metastatic colorectal cancer.
First Author: Paul Eliezer Oberstein
Poster
2021 Gastrointestinal Cancers Symposium
PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC).
First Author: John H. Strickler